FOG-001 + nivolumab

FOG-001 + nivolumab is an investigational **combination therapy** being evaluated in clinical trials for advanced or metastatic solid tumors, especially colorectal cancer. FOG-001 is a first-in-class, conformationally constrained α-helical peptide (Helicon) designed to **directly disrupt the β-catenin:TCF4 protein-protein interaction**, thus inhibiting the downstream Wnt/β-catenin signaling pathway regardless of driver mutations (APC, β-catenin). The Wnt/β-catenin pathway is a key driver of many cancers and is linked to resistance against immunotherapies, including PD-1 inhibitors like nivolumab. Preclinical and clinical data show that blocking β-catenin:TCF4 can both suppress tumor growth and reverse immune exclusion, potentially **synergizing with checkpoint inhibitors** such as nivolumab (a monoclonal antibody targeting the programmed cell death protein 1, PD-1, to enhance antitumor immune responses). The combination is being developed primarily for **microsatellite-stable colorectal cancer (MSS CRC)** and other Wnt pathway-activated malignancies, which are generally resistant to immunotherapy alone[1][2][4][5].